- Home
- IBIO vs XFOR Comparison
IBIO vs XFOR Comparison
Compare IBIO & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBIO
- XFOR
- Stock Information
- Founded
- IBIO 2008
- XFOR 2014
- Country
- IBIO United States
- XFOR United States
- Employees
- IBIO N/A
- XFOR N/A
- Industry
- IBIO Biotechnology: Pharmaceutical Preparations
- XFOR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IBIO Health Care
- XFOR Health Care
- Exchange
- IBIO Nasdaq
- XFOR Nasdaq
- Market Cap
- IBIO 11.9M
- XFOR 11.3M
- IPO Year
- IBIO N/A
- XFOR N/A
- Fundamental
- Price
- IBIO $0.79
- XFOR $3.92
- Analyst Decision
- IBIO Strong Buy
- XFOR Strong Buy
- Analyst Count
- IBIO 2
- XFOR 3
- Target Price
- IBIO $5.50
- XFOR $71.17
- AVG Volume (30 Days)
- IBIO 723.2K
- XFOR 10.7M
- Earning Date
- IBIO 09-19-2025
- XFOR 08-08-2025
- Dividend Yield
- IBIO N/A
- XFOR N/A
- EPS Growth
- IBIO N/A
- XFOR N/A
- EPS
- IBIO N/A
- XFOR N/A
- Revenue
- IBIO $375,000.00
- XFOR $32,774,000.00
- Revenue This Year
- IBIO $81.33
- XFOR $1,300.08
- Revenue Next Year
- IBIO N/A
- XFOR N/A
- P/E Ratio
- IBIO N/A
- XFOR N/A
- Revenue Growth
- IBIO 650.00
- XFOR 5721.31
- 52 Week Low
- IBIO $0.56
- XFOR $1.35
- 52 Week High
- IBIO $6.89
- XFOR $26.83
- Technical
- Relative Strength Index (RSI)
- IBIO 60.85
- XFOR 72.25
- Support Level
- IBIO $0.67
- XFOR $2.45
- Resistance Level
- IBIO $0.81
- XFOR $3.42
- Average True Range (ATR)
- IBIO 0.07
- XFOR 0.50
- MACD
- IBIO 0.02
- XFOR 0.19
- Stochastic Oscillator
- IBIO 89.29
- XFOR 99.64
About IBIO iBio Inc.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.